Expression of B-cell activating factor (BAFF) in proliferative lupus nephritis, revisited

References

• Tian J, Zhang D, Yao X, et al. Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study. Ann Rheumatic Dis. 2023;82(3):351–356. doi: 10.1136/ard-2022-223035
   PubMed Web of Science ®Google Scholar
• El Hadidi KT, Medhat BM, Abdel Baki NM, et al. Characteristics of systemic lupus erythematosus in a sample of the Egyptian population: a retrospective cohort of 1109 patients from a single center. Lupus. 2018 May;27(6):1030–1038. doi:10.1177/0961203317751856 PubMed PMID: 29431056. Epub 2018/02/13. eng.
   PubMed Web of Science ®Google Scholar
• Tektonidou MG, Dasgupta A, Ward MM. Risk of end-stage renal disease in patients with lupus nephritis, 1971-2015: a systematic review and Bayesian meta-analysis. Arthritis Rheumatol (Hoboken, NJ). 2016;68(6):1432–1441. eng. doi: 10.1002/art.39594
   PubMed Web of Science ®Google Scholar
• Moghazy A, Ibrahim AM. Mortality in a cohort of Egyptian systemic lupus erythematosus patients: retrospective two-center study. Egypt Rheumatol Rehabil. 2021 2021/02/22;48(1):14. doi: 10.1186/s43166-021-00062-5
   Google Scholar
• Arkema EV, Saleh M, Simard JF, et al. Epidemiology and damage accrual of systemic lupus erythematosus in Central Sweden: a single-center population-based cohort study over 14 years from Östergötland county. ACR Open Rheumatol. 2023 Aug;5(8):426–432. doi: 10.1002/acr2.11585 PubMed PMID: 37469135. PMCID: PMC10425583. Epub 2023/07/20. eng.
   PubMedGoogle Scholar
• Bajema IM, Wilhelmus S, Alpers CE, et al. Revision of the international society of nephrology/renal pathology society classification for lupus nephritis: clarification of definitions, and modified national institutes of health activity and chronicity indices. Kidney Int. 2018 Apr;93(4):789–796. doi: 10.1016/j.kint.2017.11.023 PubMed PMID: 29459092. Epub 2018/02/21. eng.
   PubMed Web of Science ®Google Scholar
• Parodis I, Tamirou F, Houssiau FA. Prediction of prognosis and renal outcome in lupus nephritis. Lupus Sci Med. 2020;7(1):e000389. doi:10.1136/lupus-2020-000389 PubMed PMID: 32153796. PMCID: PMC7046967. Epub 2020/03/11. eng.
   PubMed Web of Science ®Google Scholar
• Möckel T, Basta F, Weinmann-Menke J, et al. B cell activating factor (BAFF): structure, functions, autoimmunity and clinical implications in systemic lupus erythematosus (SLE). Autoimmun Rev. 2021 Feb;20(2):102736. doi:10.1016/j.autrev.2020.102736 PubMed PMID: 33333233. Epub 2020/12/18. eng.
   PubMed Web of Science ®Google Scholar
• Blair HA, Duggan ST. Belimumab: a review in systemic lupus erythematosus. Drugs. 2018 Mar;78(3):355–366. doi: 10.1007/s40265-018-0872-z PubMed PMID: 29396833. Epub 2018/02/06. eng.
   PubMed Web of Science ®Google Scholar
• Furie R, Rovin BH, Houssiau F, et al. Safety and efficacy of belimumab in patients with lupus nephritis: open-label extension of BLISS-LN study. Clin J Am Soc Nephrol. 2022 Nov;17(11):1620–1630. doi: 10.2215/CJN.02520322 PubMed PMID: 36302567. PMCID: PMC9718049. Epub 2022/10/28. eng.
   PubMed Web of Science ®Google Scholar
• Furie R, Rovin BH, Houssiau F, et al. Two-year, randomized, controlled trial of Belimumab in lupus nephritis. N Engl J Med. 2020 Sep 17;383(12):1117–1128. doi: 10.1056/NEJMoa2001180 PubMed PMID: 32937045. Epub 2020/09/17. eng.
   PubMed Web of Science ®Google Scholar
• Joy A, Muralidharan A, Alfaraj M, et al. The role of Belimumab in systemic lupus erythematosis: a systematic review. Cureus. 2022 Jun;14(6):e25887. doi: 10.7759/cureus.25887 PubMed PMID: 35844357. PMCID: PMC9277571. Epub 2022/07/19. eng.
   PubMed Web of Science ®Google Scholar
• Dean AG, Arner TG, Sunki GG, et al. Epi Info™, a database and statistics program for public health professionals. Atlanta (GA) (USA): CDC; 2011.
   Google Scholar
• Petri M, Orbai AM, Alarcón GS, et al. Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012 Aug;64(8):2677–2686. doi: 10.1002/art.34473 PubMed PMID: 22553077. PMCID: PMC3409311. Epub 2012/05/04. eng.
   PubMed Web of Science ®Google Scholar
• Bombardier C, Gladman DD, Urowitz MB, et al. Derivation of the SLEDAI. A disease activity index for lupus patients. Arthritis Rheumatol. 1992;35(6):630–640. doi: 10.1002/art.1780350606
   PubMed Web of Science ®Google Scholar
• Inker LA, Eneanya ND, Coresh J, et al. New creatinine- and cystatin C-based equations to estimate GFR without race. N Engl J Med. 2021 Nov 4;385(19):1737–1749. doi:10.1056/NEJMoa2102953 PubMed PMID: 34554658. PMCID: PMC8822996. Epub 2021/09/24. eng.
   PubMed Web of Science ®Google Scholar
• El Miedany Y, Kamel NS, Abu-Zaid MH, et al. Egyptian evidence-based consensus on clinical practice recommendations for the management of lupus nephritis. Egypt Rheumatol Rehabil. 2022;49(1):48. doi: 10.1186/s43166-022-00146-w 2022/09/13.
   Google Scholar
• Rovin BH, Adler SG, Barratt J, et al. Executive summary of the KDIGO 2021 guideline for the management of glomerular diseases. Kidney Int. 2021 Oct;100(4):753–779. doi: 10.1016/j.kint.2021.05.015 PubMed PMID: 34556300. Epub 2021/09/25. eng.
   PubMed Web of Science ®Google Scholar
• Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCT method. Methods. 2001;25(4):402–408. doi: 10.1006/meth.2001.1262 2001/12/01/.
   PubMed Web of Science ®Google Scholar
• Mok CC. Prognostic stratification of lupus nephritis: the importance of renal histology. J Rheumatol. 2023 Jun 1;50(9):1095–1096. doi: 10.3899/jrheum.2023-0381 PubMed PMID: 37263655. Epub 2023/06/02. eng.
   PubMed Web of Science ®Google Scholar
• Ishizaki J, Saito K, Nawata M, et al. Low complements and high titre of anti-Sm antibody as predictors of histopathologically proven silent lupus nephritis without abnormal urinalysis in patients with systemic lupus erythematosus. Rheumatol (Oxford). 2015 Mar;54(3):405–412. doi: 10.1093/rheumatology/keu343 PubMed PMID: 25183834. Epub 2014/09/04. eng.
   PubMed Web of Science ®Google Scholar
• Malvar A, Pirruccio P, Alberton V, et al. Histologic versus clinical remission in proliferative lupus nephritis. Nephrol Dial Transplant. 2017 Aug 1;32(8):1338–1344. doi: 10.1093/ndt/gfv296 PubMed PMID: 26250434. PMCID: PMC5837387. Epub 2015/08/08. eng.
   PubMed Web of Science ®Google Scholar
• Mackay F, Woodcock SA, Lawton P, et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med. 1999 Dec 6;190(11):1697–1710. doi: 10.1084/jem.190.11.1697 PubMed PMID: 10587360. PMCID: PMC2195729. Epub 1999/12/10. eng.
   PubMed Web of Science ®Google Scholar
• Moore PA, Belvedere O, Orr A, et al. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science. 1999 Jul 9;285(5425):260–263. doi: 10.1126/science.285.5425.260 PubMed PMID: 10398604. Epub 1999/07/10. eng.
   PubMed Web of Science ®Google Scholar
• Vincent FB, Saulep-Easton D, Figgett WA, et al. The BAFF/APRIL system: emerging functions beyond B cell biology and autoimmunity. Cytokine Growth Factor Rev. 2013 Jun;24(3):203–215. doi: 10.1016/j.cytogfr.2013.04.003 PubMed PMID: 23684423. PMCID: PMC7108297. Epub 2013/05/21. eng.
   PubMed Web of Science ®Google Scholar
• Vincent FB, Morand EF, Schneider P, et al. The BAFF/APRIL system in SLE pathogenesis. Nat Rev Rheumatol. 2014 Jun;10(6):365–373. doi: 10.1038/nrrheum.2014.33 PubMed PMID: 24614588. Epub 2014/03/13. eng.
   PubMed Web of Science ®Google Scholar
• Vincent FB, Northcott M, Hoi A, et al. Association of serum B cell activating factor from the tumour necrosis factor family (BAFF) and a proliferation-inducing ligand (APRIL) with central nervous system and renal disease in systemic lupus erythematosus. Lupus. 2013 Aug;22(9):873–884. doi: 10.1177/0961203313496302 PubMed PMID: 23846230. Epub 2013/07/13. eng.
   PubMed Web of Science ®Google Scholar
• Sari S, Cinar S, Yalcinkaya Y, et al. The relationship between serum a proliferation-inducing ligand and B-cell activating factor levels with disease activity and organ involvement in systemic lupus erythematosus. Lupus. 2022 Apr;31(5):555–564. doi: 10.1177/09612033221086123 PubMed PMID: 35249405. Epub 2022/03/08. eng.
   PubMed Web of Science ®Google Scholar
• Treamtrakanpon W, Tantivitayakul P, Benjachat T, et al. APRIL, a proliferation-inducing ligand, as a potential marker of lupus nephritis. Arthritis Res Ther. 2012 Nov 21;14(6):R252. doi: 10.1186/ar4095 PubMed PMID: 23171638. PMCID: PMC3674621. Epub 2012/11/23. eng.
   PubMed Web of Science ®Google Scholar
• Zollars E, Bienkowska J, Czerkowicz J, et al. BAFF (B cell activating factor) transcript level in peripheral blood of patients with SLE is associated with same-day disease activity as well as global activity over the next year. Lupus Sci Med. 2015;2(1):e000063. doi: 10.1136/lupus-2014-000063 PubMed PMID: 26113988. PMCID: PMC4477150. Epub 2015/06/27. eng.
   PubMed Web of Science ®Google Scholar
• Kang S, Fedoriw Y, Brenneman EK, et al. BAFF induces tertiary lymphoid structures and positions T cells within the glomeruli during lupus nephritis. J Immunol. 2017 Apr 1;198(7):2602–2611. doi: 10.4049/jimmunol.1600281 PubMed PMID: 28235864. PMCID: PMC5360485. Epub 2017/02/27. eng.
   PubMed Web of Science ®Google Scholar
• Stohl W, Hiepe F, Latinis KM, et al. Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus. Arthritis Rheum. 2012 Jul;64(7):2328–2337. doi: 10.1002/art.34400 PubMed PMID: 22275291. PMCID: PMC3350827. Epub 2012/01/26. eng.
   PubMed Web of Science ®Google Scholar
• Aringer M, Costenbader K, Daikh D, et al. European league against rheumatism/American college of rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheumatol. 2019 [2019 Sep];71(9):1400–1412. doi: 10.1002/art.40930 PubMed PMID: 31385462. PMCID: PMC6827566. Epub 2019/08/07. eng.
   PubMed Web of Science ®Google Scholar
• Marín-Rosales M, Cruz A, Salazar-Camarena DC, et al. High BAFF expression associated with active disease in systemic lupus erythematosus and relationship with rs9514828C>T polymorphism in TNFSF13B gene. Clin Exp Med. 2019;19(2):183–190. doi: 10.1007/s10238-019-00549-8 2019/05/01.
   PubMed Web of Science ®Google Scholar
• Eilertsen GØ, Ghelue M, Nossent JC. BAFF expression is increased in patients with lupus nephritis and associated with antinucleosome antibodies, C1 inhibitor, Α-1-acid-glycoprotein and endothelial activation markers. J Data Mining Genomic Proteomic. 2012;3(01). doi: 10.4172/2153-0602.1000113
   Google Scholar
• Neusser MA, Lindenmeyer MT, Edenhofer I, et al. Intrarenal production of B-cell survival factors in human lupus nephritis. Mod Pathol. 2011 Jan;24(1):98–107. doi: 10.1038/modpathol.2010.184 PubMed PMID: 20890272. Epub 2010/10/05. eng.
   PubMed Web of Science ®Google Scholar
• Marín-Rosales M, Palafox-Sánchez CA, Franco-Topete RA, et al. Renal tissue expression of BAFF and BAFF receptors is associated with proliferative lupus nephritis. J Clin Med. [2022 Dec 22];12(1). 71. doi: 10.3390/jcm12010071 PubMed PMID: 36614872. PMCID: PMC9821186. Epub 2023/01/09. eng.
   PubMed Web of Science ®Google Scholar
• Schwarting A, Relle M, Meineck M, et al. Renal tubular epithelial cell-derived BAFF expression mediates kidney damage and correlates with activity of proliferative lupus nephritis in mouse and men. Lupus. 2018 Feb;27(2):243–256. doi: 10.1177/0961203317717083 PubMed PMID: 28659046. Epub 2017/07/01. eng.
   PubMed Web of Science ®Google Scholar
• Sun CY, Shen Y, Chen XW, et al. The characteristics and significance of locally infiltrating B cells in lupus nephritis and their association with local BAFF expression. Int J Rheumatol. 2013;2013:1–9. doi: 10.1155/2013/954292 PubMed PMID: 23843794. PMCID: PMC3694495. Epub 2013/07/12. eng.
   Google Scholar
• Suso JP, Posso-Osorio I, Jiménez CA, et al. Profile of BAFF and its receptors’ expression in lupus nephritis is associated with pathological classes. Lupus. 2017;27(5):708–715. doi: 10.1177/0961203317739132 2018/04/01
   PubMed Web of Science ®Google Scholar
• Nawata A, Nakayamada S, Hisano S, et al. Differential expression of IFN-α, IL-12 and BAFF on renal immune cells and its relevance to disease activity and treatment responsiveness in patients with proliferative lupus nephritis. Lupus Sci Med. 2023 Jul;10(2). e000962. doi: 10.1136/lupus-2023-000962 PubMed PMID: 37460249. PMCID: PMC10357699. Epub 2023/07/18. eng.
   PubMed Web of Science ®Google Scholar
• Antonis F, Myrto K, Jeanette A, et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheumatic Dis. 2024;83:15–29.
   PubMedGoogle Scholar